RaySearch Laboratories CEO Johan Löf and CFO Peter Tissell said the COVID-19 pandemic continued to weigh on Q1 2021 performance, with order intake falling 52% year-on-year to SEK 145 million and net sales down 22% to SEK 182 million due to lower license sales, while recurring support revenue rose to 38% of sales. Management noted operating profit declined to SEK 12 million (8% margin) but cash flow remained strong at SEK 33 million, and said an EBITDA covenant breach led SEB to request repayment of SEK 50 million, which the company said is manageable given liquidity above SEK 200 million and net cash. The CEO highlighted product and workflow initiatives including RayStation support for Accuray’s CyberKnife, expanded machine-learning models, and improved RayStation–RayCare integration, while noting on-site demos were “very close to 0” during the pandemic and sales efforts shifted to enhanced online demos.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RaySearch Laboratories AB published the original content used to generate this news brief on February 20, 2026, and is solely responsible for the information contained therein.